Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 13/20 | 0.68 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265798 | 0.83 | HCAR3 (0.61) | HCAR3MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4238591 | 0.81 | HCAR3 (1.00) | HCAR3MEN1KMT2ACASP6 | |
| SCHEMBL400483 | 0.79 | HCAR3 (0.62) | HCAR3MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6043889 | 0.79 | HCAR3 (1.00) | HCAR3MEN1KMT2A | |
| SCHEMBL6044265 | 0.79 | HCAR3 (0.78) | HCAR3ALDH1A1CASP6 | |
| SCHEMBL2338616 | 0.78 | HCAR3 (1.00) | HCAR3MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6044169 | 0.78 | HCAR3 (1.00) | HCAR3MEN1KMT2A | |
| SCHEMBL6044135 | 0.78 | HCAR3 (1.00) | HCAR3MEN1KMT2A | |
| SCHEMBL2292537 | 0.77 | HCAR3 (0.58) | HCAR3KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2426051 | 0.76 | HCAR3 (0.71) | HCAR3MEN1KMT2ACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885DOT1L 4718/4885MEN1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.